{
    "Clinical Trial ID": "NCT00876395",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Everolimus + Paclitaxel + Trastuzumab",
        "  Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22",
        "INTERVENTION 2: ",
        "  Placebo + Paclitaxel + Trastuzumab",
        "  Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Adult Women ( 18 years old).",
        "  Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.",
        "  Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.",
        "  HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).",
        "  Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued > 12 months prior to randomization.",
        "  Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.",
        "  Documentation of negative pregnancy test.",
        "  Organ functions at time of inclusion.",
        "Exclusion Criteria:",
        "  Prior mTOR inhibitors for the treatment of cancer.",
        "  Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy.",
        "  Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).",
        "  Radiotherapy to  25% of the bone marrow within 4 weeks prior to randomization",
        "  History of central nervous system metastasis.",
        "  Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.",
        "  Serious peripheral neuropathy.",
        "  Cardiac disease or dysfunction.",
        "  Uncontrolled hypertension.",
        "HIV.",
        "Pregnant,"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-free Survival (PFS) Per Investigators' Assessment Based on Local Radiology Review - Full Population",
        "  PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first. This was assessed in the full patient population.",
        "  Time frame: date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 56 months",
        "Results 1: ",
        "  Arm/Group Title: Everolimus + Paclitaxel + Trastuzumab",
        "  Arm/Group Description: Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22",
        "  Overall Number of Participants Analyzed: 480",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  14.95        (14.55 to 17.91)",
        "Results 2: ",
        "  Arm/Group Title: Placebo + Paclitaxel + Trastuzumab",
        "  Arm/Group Description: Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22",
        "  Overall Number of Participants Analyzed: 239",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  14.49        (12.29 to 17.08)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 173/472 (36.65%)",
        "  Anaemia 6/472 (1.27%)",
        "  Febrile neutropenia 4/472 (0.85%)",
        "  Iron deficiency anaemia 1/472 (0.21%)",
        "  Leukopenia 2/472 (0.42%)",
        "  Neutropenia 2/472 (0.42%)",
        "  Thrombocytopenia 4/472 (0.85%)",
        "  Acute myocardial infarction 1/472 (0.21%)",
        "  Aortic valve incompetence 0/472 (0.00%)",
        "  Atrial fibrillation 2/472 (0.42%)",
        "  Cardiac arrest 1/472 (0.21%)",
        "Adverse Events 2:",
        "  Total: 40/238 (16.81%)",
        "  Anaemia 0/238 (0.00%)",
        "  Febrile neutropenia 1/238 (0.42%)",
        "  Iron deficiency anaemia 0/238 (0.00%)",
        "  Leukopenia 0/238 (0.00%)",
        "  Neutropenia 2/238 (0.84%)",
        "  Thrombocytopenia 0/238 (0.00%)",
        "  Acute myocardial infarction 0/238 (0.00%)",
        "  Aortic valve incompetence 1/238 (0.42%)",
        "  Atrial fibrillation 0/238 (0.00%)",
        "  Cardiac arrest 0/238 (0.00%)"
    ]
}